Principal investigators in the Exenatide-115 Clinical Study Group were L. Abbott,A. Ahmann, J. Albu, R. Arakaki, L.Blonde, J. Buse, E. Busick, P. Casner, L.Chaykin, R. Cherlin, M. Chertman, A.J.Cohen, J. Cohen, G. Collins, L. Corn, J.Cyrus, L. Davis, R. DeFronzo, C. de laGarza, S. Duckor, J. Durden, T. Doty, J.Farrell, M.H. Farooqi, N. Fishman, L. Fo-gelfeld, W. Gaman, S. Garg, W.T. Garvey,L. Gavin, J. Gilbert, B. Goldstein, A.Gupta, W. Harvey, I. Hartman, C. Her-ring, B. Horowitz, W. Isley, D. James, R.Juneja, R. Kaplan, D. Kayne, D. Kendall,E. Klein, T. Knecht, J. Kopin, S. Leichter,M. Magee, S. Magill, D. Martinez, R.McInroy, J. Miller, S. Miller, R. Mills, T.Moretto, P. Moriarty, S. Mudaliar, L. My-ers, D. Normandin, P. Norwood, L. Olan-sky, K. Osei, J. Pappas, A. Philis-Tsimikas, J. Pullman, A. Radparvar, P.Reith, L.R. Reynolds, D. Riff, J. Robinson,R. Rood, J. Rosenstock, S